ProCE Banner Activity

Incorporating Targeted Therapies Into Multidisciplinary Care for Advanced Systemic Mastocytosis

Slideset Download
Review this slideset on the optimal management of advanced systemic mastocytosis using targeted agents.

Released: April 12, 2022

Expiration: April 11, 2023

No longer available for credit.

Share

Faculty

Prithviraj Bose

Prithviraj Bose, MD

Professor
Department of Leukemia
UT MD Anderson Cancer Center
Houston, Texas

Ilene A. Galinsky

Ilene A. Galinsky, NP

Senior Research Program Adult Leukemia Nurse Practitioner
Department of Leukemia
Dana-Farber Cancer Institute/Brigham and Womens Hospital
Boston, Massachusetts

Caitlin R. Rausch

Caitlin R. Rausch, PharmD, BCOP

Clinical Pharmacy Specialist, Leukemia
MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Blueprint Medicines

Faculty Disclosure

Primary Author

Prithviraj Bose, MD

Professor
Department of Leukemia
UT MD Anderson Cancer Center
Houston, Texas

Prithviraj Bose, MD, has disclosed that he has receiving consulting fees from AbbVie, Blueprint Medicines, Bristol-Myers Squibb, CTI BioPharma, Incyte, Karyopharm, Novartis, Pharma Essentia, and Sierra Oncology and funds for research support from Astellas, Blueprint Medicines, Bristol-Myers Squibb, Cogent, Constellation, CTI BioPharma, Incyte, Ionis, Kartos, NS Pharma, Pfizer, and Promedior.

Ilene A. Galinsky, NP

Senior Research Program Adult Leukemia Nurse Practitioner
Department of Leukemia
Dana-Farber Cancer Institute/Brigham and Womens Hospital
Boston, Massachusetts

Ilene A. Galinsky, NP, has disclosed that she has received consulting fees from AbbVie, Jazz, Novartis, and Pfizer.

Caitlin R. Rausch, PharmD, BCOP

Clinical Pharmacy Specialist, Leukemia
MD Anderson Cancer Center
Houston, Texas

Caitlin R. Rausch, PharmD, has no relevant conflicts of interest to report.